A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
- Martin H. Voss
- , Rupal S. Bhatt
- , Nicholas J. Vogelzang
- , Mayer N. Fishman
- , Robert Alter
- , Brian I. Rini
- , J. Thaddeus Beck
- , Monika Joshi
- , Ralph J. Hauke
- , Michael B. Atkins
- , Earle Burgess
- , Theodore F. Logan
- , David Shaffer
- , Rahul Parikh
- , Nauman Moazzam
- , Xiaosha Zhang
- , Chad Glasser
- , Matthew L. Sherman
- , Elizabeth R. Plimack
- Memorial Sloan-Kettering Cancer Center
- Beth Israel Deaconess Medical Center
- University of South Florida
- Rutgers - The State University of New Jersey, Newark
- Cleveland Clinic Foundation
- Highlands Oncology Group
- Pennsylvania State University
- Methodist Health System, Nebraska
- Georgetown University
- Carolinas Medical Center
- Indiana University Bloomington
- New York Oncology Hematology
- University of Pittsburgh
- Rocky Mountain Cancer Centers
- Acceleron Pharma Inc
- Cornell University
- Comprehensive Cancer Centers of Nevada
- US Oncology Network
- Nevada Cancer Research Foundation
- John Theurer Cancer Center
- Vanderbilt University
- Oncology Heamatology Care Inc.
- Nebraska Cancer Specialists
- Tufts University
- MedStar Georgetown University Hospital
- Acceleron Pharma
Research output: Contribution to journal › Article › peer-review
23
Scopus
citations